NCT07584330Recruiting
AI-Driven Metabolic Cohort in Overweight/Obese Chinese Adults
Chinese Overweight/Obese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight/obesity to unhealthy overweight/obesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight/obesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight/obesity, metabolically unhealthy overweight/obesity, and type 2 diabetes with overweight/obesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2800 (estimated)
- First submitted
- 7 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Apr 2032
- Lead sponsor
- Zhujiang Hospital
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07584330
What you commit to
- Study type: Observational
- Planned participants: 2800
- From 1 Jul 2026 to the primary completion date, 1 Apr 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.
- Concurrent participation in another interventional clinical trial that may influence the results of this study.
Other illness
- Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.
- Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \< 0.1 mIU/L with FT4 \> upper normal limit; hypothyroidism: TSH \> 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.
- Severe liver disease (Child-Pugh class B or C).
- Renal insufficiency (estimated glomerular filtration rate \< 30 mL/min/1.73 m²).
- Severe cardiac dysfunction (New York Heart Association class III or IV).
- Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).
- Active malignancy (diagnosed or treated within the last 3 years).
- Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).
- Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).
- Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).
- History of or planned organ transplantation.
Lab values
- Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).
Other
- Pregnancy or planned pregnancy during the study period.
- Inability to operate the AI-based system or comply with follow-up procedures.
- Unwilling or unable to provide informed consent.
Who the study is looking for
- Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.
- Age between 18 and 60 years (inclusive).
- Meets at least one of the following overweight/obesity criteria: a) BMI ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.
- Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhujiang Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.